The most frequent alterations leading to the activation of the CDK4/6 pathway in GBM are co-deletions of the CDKN2A and CDKN2B loci (56%), amplification of CDK4 (14%), and deletion of RB1 (7.9%) [7]. The gene discussed is CDKN2A; the disease is glioblastoma.